a shorter course of treatment with azithromycin does not involve a shorter duration of antibiotic exposure.
1. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010 -2011 . JAMA. 2016 315(17) :1864-1873.
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Hersh AL, Fleming-Dutra KE, Shapiro DJ, Hyun DY, Hicks LA; Outpatient Antibiotic Use Target-Setting Workgroup. Frequency of first-line antibiotic selection among US ambulatory care visits for otitis media, sinusitis, and pharyngitis. JAMA Intern Med. 2016; 176(12) :1870-1872. 
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Clinical Usefulness of Imaging and Blood Cultures in Cellulitis Evaluation
Cellulitis is a commonly occurring acute bacterial skin infection of the dermis and subcutaneous skin. In the United States, there are approximately 14.5 million cases of cellulitis annually, resulting in 650 000 hospital admissions. Table 2) . None of the patients imaged were febrile or neutropenic, indicating that all imaging performed was contraindicated by IDSA guidelines. Imaging results changed diagnosis and management in 8 patients (6.5%), who had alternative diagnoses of hematoma (n = 1), abscess (n = 5), and osteomyelitis (n = 2). While 4 instances (36.4%) of magnetic resonance imaging led to changes in patient management, only a small fraction of computed tomography (n = 2 patients [6.9%]), radiographs (n = 2 patients [1.5%]), and ultrasonography (n = 1 patient [1.0%]) changed diagnosis and treatment.
Comparing patients who did and did not receive imaging, we found that those who underwent imaging had a significantly higher percentage of chronic lymphedema (n = 36 [29.0%] vs n = 9 [15.3%]; P = .04) and higher mean levels of serum glucose (133.1 vs 116.3; P = .03). There was no significant difference in other cellulitis risk factors or laboratory values between the 2 groups.
Based on estimates of imaging and blood culture costs, the yearly cellulitis hospitalization rate, and the rate at which imaging and blood cultures were ordered within this patient cohort, the cost of these largely clinically useless diagnostic studies is approximately $226.9 million dollars annually.
Discussion | The majority of patients with cellulitis received 1 or more imaging modalities, despite IDSA guidelines that recommend against imaging except in patients who are also experiencing febrile neutropenia.
2 Results of blood cultures and imaging seldom altered diagnosis or treatment. As previous studies have suggested, 4-6 radiologic imaging and blood cultures have low clinical usefulness for evaluation and treatment of cellulitis. In addition, they portend significant cost to the health care system. Imaging and blood cultures should be pursued only in patients who are severely immunocompromised or experiencing systemic toxic effects. 
Conflicts of Interest of Public Speakers at Meetings of the Anesthetic and Analgesic Drug Products Advisory Committee
In 2017, an US Food and Drug Administration (FDA) workshop on opioid safety drew Congressional scrutiny because advocacy groups participating in the meeting had financial ties to opioid manufacturers. 1 Little formal attention, however, has been paid to the possibility of such conflicts of interest among patients and advocates who appear as public speakers before the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC), which advises the FDA on drug products used in anesthesiology and pain management. In addition to presentations from the sponsor of the drug under review and FDA staff, AADPAC meetings include an open hearing during which public speakers can address the committee. These speakers are encouraged, but not required, to disclose conflicts of interest.
Building on a study of public speakers at meetings of the FDA's Oncologic Drugs Advisory Committee, 2 we investigated the characteristics and conflicts of interest of public speakers at AADPAC meetings.
Methods | This study was an investigation of published reports and public websites and therefore was not subject to institutional review board approval according to federal regulations. We collected data from August through November 2017.
First, we identified AADPAC meetings from September 2009 (the earliest date on the AADPAC's primary archive page) through April 2017 related to the approval of drug products. Second, we reviewed meeting transcripts, recording whether public speakers (1) reported experiencing chronic pain; (2) had received the drug under review; (3) reported an organizational affiliation; (4) reported a conflict of interest; and (5) expressed support, opposition, or were neutral with respect to drug approval. Third, where speakers reported an organizational affiliation but disclosed no conflict of interest, we performed a Google search for evidence of financial associations between the sponsor and the speaker's organization. We coded financial associations as existing prior to the meeting or of indeterminate date.
Using logistic regression models that accounted for clustering at the speaker level, we estimated statistical associations between whether a speaker had a conflict of interest and whether the speaker supported drug approval. We estimated 3 models, each with a different conflict of interest measure: (1) disclosed conflicts; (2) disclosed and undisclosed conflicts where undisclosed financial associations of indeterminate date were assumed to originate after testimony and, therefore, were not classified as conflicts; and (3) disclosed and undisclosed conflicts where undisclosed financial associations of indeterminate date were classified as conflicts.
Results | From September 2009 to April 2017, there were 15 AADPAC meetings related to drug approval at which 91 individuals made 112 speaking appearances. In these appearances, 20 speakers reported having experienced chronic pain and 11 reported receiving the drug under review (Table) . Of the 112 speakers, 22 (19.6%) disclosed a conflict of interest, most frequently reimbursement by the sponsor for travel or other 
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